Folks stroll by way of electrical truck maker Rivian’s newly opened storefront within the Meatpacking District of Long island on June 23, 2023 in New York Town.
Spencer Platt | Getty Pictures
Take a look at the firms making headlines in noon buying and selling.
Electrical automobiles — Electrical automobile makers similar to Rivian Automobile surged following Tesla’s better-than-expected second-quarter manufacturing and supply numbers. Rivian jumped 14%, Fisker rose 4% and Lucid Staff complex 5%.
XPeng — The U.S.-listed stocks of XPeng climbed greater than 4%. The Chinese language electrical automobile maker returned to expansion for automobile deliveries. In the second one quarter, it delivered 23,205 automobiles, a 27% quarter-over-quarter build up.
Tesla — Stocks of the the Elon Musk-led electrical automobile corporate jumped 6% after supply and manufacturing numbers beat analysts’ expectancies. The second one quarter of 2023 marked the 5th in a row when Tesla reported a better degree of automobiles produced when compared with deliveries.
Chinese language web shares — China-based era names rose on Monday. The KraneShares CSI China Web ETF added greater than 3%, lifted by way of stocks of Alibaba, upper by way of 1%, and Pinduoduo, forward 4%. Stocks of JD.com won 4%.
Sun shares — Sun shares SolarEdge Applied sciences and Enphase Power rose greater than 2% and 1%, respectively, on Monday.
Semiconductors — Semiconductor names rose on Monday. Stocks of Marvell Generation and Micron Generation had been each and every upper by way of greater than 1%.
Apple — Apple declined 0.5% after the Monetary Instances, mentioning other folks with direct wisdom of the topic, reported the iPhone maker used to be compelled to chop manufacturing forecasts for its Imaginative and prescient Professional headset. Apple stocks closed above a $3 trillion marketplace price on Friday.
AstraZeneca — Stocks sank about 8% after the Cambridge, England-based drugmaker introduced disappointing initial effects for a segment 3 trial of a lung most cancers remedy. AstraZeneca mentioned it slowed development of the most cancers, however the knowledge for general survival used to be “now not mature” and the consequences weren’t statistically vital. The trial will proceed to evaluate general survival with better adulthood, the corporate mentioned.
— CNBC’s Michelle Fox and Yun Li contributed reporting